Fig. 6: Effects of XCL1-OT-I in combination with anti-PD-1 Ab.

a Expression of an immune checkpoint molecule, PD-1, on CD8⁺CD62L⁻ T cells. Mice were unimmunised (PBS) or immunised with OT-I peptide or XCL1-OT-I plus poly(I:C). Seven days after immunisation, splenocytes were prepared, stimulated with OT-I and analysed by a flow cytometer. Representative dot plots are shown. b, c Effects of XCL1-OT-I and anti-PD-1 Ab in the therapeutic tumour model. Mice were inoculated with B16-OVA on day 0, and immunised with PBS only, or 2 µg of XCL1-OT-I plus 20 µg of poly(I:C) on days 7 and 14. Anti-PD-1 Ab was administered on days 14, 17 and 21. Tumour volumes at indicated days and survival analysis are shown (n = 5 for each group). Similar data were obtained from two independent experiments. *, **p < 0.05, with ANOVA test. s.c., subcutaneously. i.p., intraperitoneal.